Publication reviews efficacy of Lorus’ interleukin 17E
February 24, 2010 by leonardzehr · Leave a Comment
Lorus Therapeutics (TSX:LOR) reports that the peer-reviewed journal, Cancer Immunology Immunotherapy, has published an article that outlines the anti-tumour activity of a novel cytokine interleukin 17E (IL-17E) and data of its mechanism of action. In the article, Lorus scientists demonstrated the anti-tumour effects of IL-17E in preclinical models, using it alone and in combination with [...]
Listen to BioTuesdays 
